WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

Amgen's Tavneos, facing liver injury scrutiny, gets label update in Japan as patient starts resume

After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once again prescribe Amgen’s rare autoimmune disease med Tavneos (avacopan), alb | After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once again prescribe Amgen’s rare autoimmune disease med Tavneos (avacopan), albeit with revised safety precautions tucked into the product packaging.

Raccontata daendpoints.newsfiercepharma.com

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
fiercepharma.comStai leggendo3 g fa

Amgen's Tavneos, facing liver injury scrutiny, gets label update in Japan as patient starts resume

After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once again prescribe Amgen’s rare autoimmune disease med Tavneos (avacopan), alb | After the drug’s…

originale
endpoints.news6 g fa

Amgen stands by Tavneos, despite reports of 20 deaths in Japan

The FDA wants Amgen's Tavneos off the market. European regulators are investigating data-integrity concerns. And now, a pharma selling the drug in Japan is warning doctors against writing more prescriptions.

Leggi questa versione →

Timeline cronologica

  1. lunedì 18 maggio 2026·endpoints.news

    Amgen stands by Tavneos, despite reports of 20 deaths in Japan

    The FDA wants Amgen's Tavneos off the market. European regulators are investigating data-integrity concerns. And now, a pharma selling the drug in Japan is warning doctors against…

  2. giovedì 21 maggio 2026·fiercepharma.com

    Amgen's Tavneos, facing liver injury scrutiny, gets label update in Japan as patient starts resume

    After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once again prescribe Amgen’s rare autoimmune disease med…

originale
  • venerdì 22 maggio 2026·fiercepharma.com

    Fierce Pharma Asia—Merck-Kelun ADC’s triple wins; Tools in China licensing deals; Takeda’s $885M antitrust loss

    Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. | Merck & Co. and Kelun-Biotech's sac-TMT is on fire…

  • venerdì 22 maggio 2026·fiercepharma.com

    AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway

    The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is…